Cargando…
Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells
SIMPLE SUMMARY: Although metastatic melanoma is still not a curable disease, targeting of immunologically relevant checkpoints represents a turning point in the treatment. Particularly, targeting the interaction between PD-L1 and its referring receptor PD-1 with antibodies has been shown to activate...
Autores principales: | Kleemann, Johannes, Steinhorst, Katja, König, Veronika, Zöller, Nadja, Cinatl, Jindrich, Özistanbullu, Deniz, Kaufmann, Roland, Meissner, Markus, Kippenberger, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562717/ https://www.ncbi.nlm.nih.gov/pubmed/36230620 http://dx.doi.org/10.3390/cancers14194698 |
Ejemplares similares
-
CpG Oligonucleotides as Cancer Vaccine Adjuvants
por: Shirota, Hidekazu, et al.
Publicado: (2015) -
In Vivo Control of CpG and Non-CpG DNA Methylation by DNA Methyltransferases
por: Arand, Julia, et al.
Publicado: (2012) -
Preservation of methylated CpG dinucleotides in human CpG islands
por: Panchin, Alexander Y., et al.
Publicado: (2016) -
The revival of CpG oligonucleotide-based cancer immunotherapies
por: Adamus, Tomasz, et al.
Publicado: (2018) -
Suppressive CpG
por: Van Epps, Heather L.
Publicado: (2005)